si-b001

mAbexperimentalBi-specific

Clinical trial activity

11 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
8
Phase 3
3
Phase 4
0

Earliest trial started May 11, 2020 (NCT04603287)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06668961Phase 2Nov 30, 2024Baili Pharmaceutical Group
NCT05949606Phase 1/Phase 2 (Phase 2)Oct 30, 2023Baili Pharmaceutical Group, Huazhong University of Science and Technology
NCT05943795Phase 3Jul 14, 2023Baili Pharmaceutical Group, Sun Yat-Sen University
NCT05668858Phase 1/Phase 2 (Phase 2)Dec 31, 2022Baili Pharmaceutical Group, Shanghai Oriental Hospital
NCT05020769Phase 2/Phase 3 (Phase 3)Oct 1, 2021Baili Pharmaceutical Group, Sun Yat-Sen University
NCT05020457Phase 2/Phase 3 (Phase 3)Oct 1, 2021Baili Pharmaceutical Group, Sun Yat-Sen University
NCT05054439Phase 2Sep 30, 2021Baili Pharmaceutical Group
NCT05044897Phase 2Sep 30, 2021Baili Pharmaceutical Group, Shanghai Oriental Hospital
NCT05039944Phase 2Sep 20, 2021Baili Pharmaceutical Group, Fudan University
NCT05022654Phase 2Sep 1, 2021Baili Pharmaceutical Group, Chinese Academy of Medical Sciences
NCT04603287Phase 1May 11, 2020Baili Pharmaceutical Group, Sun Yat-Sen University, SystImmune Inc.
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Baili Pharmaceutical GroupFor profit111132020
Sun Yat-Sen UniversityAcademic/Hospital4022020
Shanghai Oriental HospitalAcademic/Hospital2012021
Chinese Academy of Medical SciencesAcademic/Hospital1012021
Fudan UniversityAcademic/Hospital1012021
Huazhong University of Science and TechnologyAcademic/Hospital1012023
SystImmune Inc.For profit1012020
7 organizations
Page 1 / 1